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Inflammation is increasingly recognized as a driver of hypertension. Both genetic and
pharmacological inhibition of B and T cells attenuates most forms of experimental
hypertension. Accordingly, the immunosuppressive drug mycophenolate mofetil (MMF)
reduces blood pressure in the deoxycorticosterone acetate (DOCA-) salt model.
However, the mechanisms by which MMF prevent hypertension in the DOCA-salt model
remain unclear. Recent studies indicate that immunosuppression can inhibit sodium
transporter activity in the kidney, but its effect on vascular tone is not well characterized.
Therefore, the aim of the present study was to analyze the vascular and renal tubular
effects of MMF in the DOCA-salt model in rats (4 weeks without uninephrectomy). Co-
treatment with MMF attenuated the rise in blood pressure from day 11 onward resulting
in a significantly lower telemetric mean arterial pressure after 4 weeks of treatment
(108 ± 7 vs. 130 ± 9 mmHg, P < 0.001 by two-way analysis of variance). MMF
significantly reduced the number of CD3+ cells in kidney cortex and inner medulla,
but not in outer medulla. In addition, MMF significantly reduced urinary interferon-γ
excretion. Vascular tone was studied ex vivo using wire myographs. An angiotensin II
type 2 (AT2) receptor antagonist blocked the effects of angiotensin II (Ang II) only in the
vehicle group. Conversely, L-NAME significantly increased the Ang II response only in the
MMF group. An endothelin A receptor blocker prevented vasoconstriction by endothelin-
1 in the MMF but not in the vehicle group. MMF did not reduce the abundances of
the kidney sodium transporters NHE3, NKCC2, NCC, or ENaC. Together, our ex vivo
results suggest that DOCA-salt induces AT2 receptor-mediated vasoconstriction. MMF
prevents this response and increases nitric oxide availability. These data provide insight
in the antihypertensive mechanism of MMF and the role of inflammation in dysregulating
vascular tone.
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INTRODUCTION
Hypertension is one of the major risk factors for cardiovascular and kidney disease, and therefore
an important cause of premature morbidity and mortality. The pathogenesis of hypertension is
multifactorial and the result of a complex interplay between dietary and genetic factors, hormones,
nerves, and blood pressure regulating organs, including the nervous system, kidneys, heart, and
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vasculature. Of interest, an increasing body of evidence suggests
that inflammation is another driver of hypertension (McMaster
et al., 2015; Wenzel et al., 2016; Crowley and Rudemiller, 2017;
Foss et al., 2017).
For example, Svendsen (1976) reported that nude mice,
which also have genetic aplasia of the thymus, became less
hypertensive in response to deoxycorticosterone acetate (DOCA)
and salt than haired mice. Similarly, subcutaneous administration
of rabbit anti-rat thymocyte serum reduced blood pressure
in spontaneously hypertensive rats (SHRs) (Bendich et al.,
1981). Intravenous injection of splenic cells from DOCA-salt-
treated rats transferred arterial hypertension to recipient rats
(Olsen, 1980). Angiotensin II (Ang II)-induced hypertension is
attenuated in genetic mouse models lacking B and T lymphocytes
(Guzik et al., 2007; Crowley et al., 2010).
Pharmacological inhibition of B and T cells with the
immunosuppressive drug mycophenolate mofetil (MMF) can
also exert anti-hypertensive effects. Although MMF did not
modify hypertension during exogenous Ang II infusion, it
did prevent the subsequent development of salt-sensitive
hypertension (Rodriguez-Iturbe et al., 2001). MMF did normalize
blood pressure in SHRs and Dahl salt-sensitive rats (Rodriguez-
Iturbe et al., 2002; Mattson et al., 2006). Similarly, MMF
attenuated hypertension and albuminuria in uninephrectomized
rats treated with DOCA-salt (Boesen et al., 2010). The anti-
hypertensive effects of MMF were not only observed in
experimental settings, but also in patients with psoriasis or
rheumatoid arthritis treated with MMF (Herrera et al., 2006).
It is incompletely understood how genetic or pharmacological
inhibition of B and T cells prevents hypertension. Several
studies have shown reduced renal infiltration of lymphocytes and
macrophages in MMF-treated hypertensive animals (Rodriguez-
Iturbe et al., 2002; Franco et al., 2007, 2013). More recently, such
infiltrations have been linked to activation of sodium transporters
through direct effects or secretion of cytokines (Kamat et al.,
2015; Zhang et al., 2016; Liu et al., 2017). However, few studies
have analyzed the effects of immunosuppression on vascular
function in experimental hypertension.
Here, we hypothesize that B and T cells mediate experimental
hypertension not only through effects on renal sodium transport
but also on vascular tone. To do so, we induced hypertension
with DOCA-salt in rats and co-treated the animals with MMF
or vehicle. Using ex vivo myograph analysis of vascular tone,
we show that MMF suppresses Ang II type 2 (AT2) receptor-
mediated vasoconstriction and increases nitric oxide (NO)
availability.
MATERIALS AND METHODS
Animal Experiments
The animal protocol was approved by the Animal Care
Committee of the Erasmus Medical Center (EMC 3101, # 127-
13-01). Sixteen male Sprague-Dawley rats (20 weeks old, average
weight 350 g) were obtained from Charles River Laboratories
(Sulzfeld, Germany). Animals were randomized to a treatment
and a vehicle group (n = 8/group). All animals were housed
in individual cages and maintained on a 12-h light–dark cycle,
having ad libitum access to water and standard laboratory rat
chow (Na+ 0.5%, K+ 0.8%). Radiotelemetry transmitters were
implanted in eight rats (n = 4/group) for continuous blood
pressure measurement as described before (van Esch et al., 2010).
After a 14-day recovery period, 200 mg 60-day continuous-
release DOCA pellets (Innovative Research of America, Sarasota,
United States) were implanted subcutaneously in all rats. From
this day on, regular drinking water was replaced by 0.9% NaCl
for all rats. Rats in the treatment group received a daily dose of
30 mg/kg of MMF (Boesen et al., 2010) via gastric gavage and
control rats received an equal volume of water (vehicle). Once
a week, animals were placed in metabolic cages for 24 h for the
collection of urine and the measurement of food and 0.9% NaCl
intake. After 28 days, all animals were killed by left ventricular
puncture.
Biochemical Measurements
Urinary sodium, potassium, and total protein were measured
by the Department of Clinical Chemistry of the Erasmus
Medical Center. Endothelin-1 (ET-1) in plasma and urine
was determined by chemiluminescent ELISA (QuantiGlo,
R&D Systems, Abingdon, United Kingdom). A Milliplex
cytokine/chemokine immunoassay (Merck Millipore, Billerica,
MA, United States) was used for the measurement of interferon-
γ (IFN-γ), interleukin-6 (IL-6), chemokine (C-C motif) ligand 5
(CCL5), and tumor necrosis factor-α (TNF-α) in urine.
Tissue Preparation
After blood collection, kidneys were rapidly excised, weighed, and
placed on ice.
The left kidneys of four rats of each group were immersion-
fixed in paraformaldehyde and further processed for
immunohistochemistry. The right kidneys were used for
immunoblotting and were placed in an isolation buffer
containing 250 mM sucrose, 10 mM triethanolamine, and a
protease inhibitor mix (cOmplete Protease Inhibitor Cocktail
Tablets, Roche Diagnostics, Almere, Netherlands) before
homogenization. Differential centrifugation of the whole kidney
homogenate was performed to obtain a plasma membrane-
enriched fraction, as described previously (Ecelbarger et al.,
1997; van der Lubbe et al., 2011). The pellet (plasma membrane-
enriched fraction) was resuspended in 1 mL of isolation buffer.
A total of 60 µL of both fractions was used for a protein
quantification assay (Pierce, Thermo Scientific, Rockford, IL,
United States) and the remaining samples were stored in 6×
Laemmli buffer at−80◦C until immunoblotting.
Immunohistochemistry
Transverse kidney sections were dehydrated and paraffin-
embedded, 4-µm sections were cut on a rotary microtome.
Staining procedures were performed on the Ventana Benchmark
Ultra automatic stainer. For antigen retrieval, deparaffinized
sections were incubated with Cell Conditioning 1 medium
(Ventana Medical Systems, Tucson, AZ, United States) at 100◦C
for 32 min. For immunolabeling, slides were incubated in the
presence or absence of a polyclonal rabbit anti-CD3ε antibody
Frontiers in Physiology | www.frontiersin.org 2 May 2018 | Volume 9 | Article 578
fphys-09-00578 May 16, 2018 Time: 17:48 # 3
Moes et al. Mycophenolate Mofetil in DOCA-Salt Hypertension
(1:600, Novus Biologicals, Abingdon, United Kingdom) at 36◦C
for 32 min, followed by an 8-min incubation with a secondary
antibody (Optiview HQ Universal Linker) at 36◦C. Detection
and visualization was done by subsequent 8-min incubations
at 36◦C with Optiview HRP Multimer and diaminobenzidine
(all from Ventana Medical Systems), after which slides were
counterstained with hematoxylin. A rat spleen sample was used
as positive control. CD3+ cells were counted in 20 randomly
selected 400 µm × 200 µm fields in cortex, outer and inner
medulla by an investigator blinded to treatment allocation (D.S.).
Results are expressed as positive cell counts per mm2.
Immunoblotting
Immunoblotting was performed as described previously (Kim
et al., 1998). Antibodies against the following proteins were used:
sodium hydrogen exchanger type 3 (NHE3, dilution 1:5000),
sodium potassium chloride co-transporter 2 (NKCC2, 1:1000),
sodium chloride co-transporter (1:500) and its phosphorylated
form at threonine-58 (pNCC, 1:500), and the α- and γ-subunits
of the epithelial sodium channel (ENaC, both 1:1000). All
antibodies were purchased from StressMarq (Victoria, BC,
Canada), except for NCC (Merck Millipore, Billerica, MA,
United States) and pNCC (a kind gift by Dr. R. A. Fenton;
Pedersen et al., 2010). β-Actin (1:50,000, Abcam) was used for
normalization of protein levels. Protein was visualized using
horseradish peroxidase-conjugated secondary antibodies (1:3000,
Bio-Rad, Veenendaal, Netherlands). Signals were detected
by chemiluminescence (Pierce, Rockford, IL, United States),
quantified using ImageQuant LAS 4000 (GE Healthcare, Diegem,
Belgium), and normalized to actin.
Wire Myograph Studies
Following isolation and after overnight storage, iliac and
mesenteric arteries were cut into segments of approximately
2 mm length and mounted in a Mulvany myograph with
separated 6-mL organ baths containing carbogen-gassed Krebs–
Henseleit buffer at 37◦C. First order mesenteric arteries were
used for this experiment, and iliac and mesenteric arteries
were used because of their excellent and highly reproducible
response to Ang II and ET-1, respectively (Batenburg et al.,
2013; Roksnoer et al., 2015). The tension was normalized to
0.9 times the estimated diameter at 100 mmHg of effective
transmural pressure. The presence of endothelium was verified
by observing relaxation to 1 mM acetylcholine (ACh) after
preconstriction with 100 nM of the thromboxane A2 analog
U46619 (9,11-dideoxy-11a,9a-epoxy-methanoprostaglandin F2a,
Sigma-Aldrich, Zwijndrecht, Netherlands). To determine the
maximum contractile response, the tissue was exposed to
100 mM KCl. The segments were then allowed to equilibrate in
fresh organ bath fluid for 30 min in the absence or presence
of 1 µM of irbesartan, 1 µM of PD123319 (Sigma-Aldrich),
100 µM of NG-nitro-L-arginine methyl ester (L-NAME, Sigma-
Aldrich), 1 µM of BQ123 (a selective ETA endothelin receptor
antagonist), or 1 µM of BQ788 (a selective ETB endothelin
receptor antagonist). Thereafter, concentration–response curves
(CRCs) were constructed in response to Ang II (iliac arteries)
or ET-1 (mesenteric arteries). ACh-induced relaxation was
measured in ET-1 CRCs.
Statistical Analysis
All data are expressed as means and standard error of the mean.
Blood pressure data were analyzed using repeated measures
analysis of variance (ANOVA). CRCs were analyzed as described
before (MaassenVanDenBrink et al., 1999) to determine the
maximum effect (Emax) and pEC50 (= −10logEC50) values.
Contractile responses to Ang II or ET-1 are expressed as a
percentage of the contraction to 100 mM KCl. Relaxation
responses to ACh are expressed as a percentage of the
contraction to U46619. CRC and relaxation response data,
immunohistochemical CD3+ cell quantification data, and log-
transformed cytokine/chemokine data were analyzed by one-way
ANOVA, with Dunnett’s post hoc test where appropriate. P< 0.05
was considered statistically significant.
RESULTS
Biochemical Responses
DOCA-salt induced an increase in fluid intake, diuresis,
and urinary Na+ and K+ excretion, which was sustained
throughout the 4-week period (Figure 1). Co-treatment with
MMF significantly attenuated fluid intake, diuresis, and urinary
Na+ and K+ excretion. Food intake was unaffected by co-
treatment with MMF. The body weight at day 28 did not
differ between the MMF and vehicle-treated animals, respectively
(492 ± 12 vs. 474 ± 16 grams, P = 0.4). Median ET-1 levels
in serum (0.84 vs. 0.85 pg/mL) and urine (0.09 vs. 0.08 pg/mL)
and proteinuria (0.16 vs. 0.14 g/L) were not different between the
MMF and vehicle-treated animals, respectively.
Blood Pressure Response
DOCA-salt caused a continuing rise in mean arterial pressure
(MAP) over the 4-week period (from 101± 4 to 130± 8 mmHg;
Figure 2). Co-treatment with MMF attenuated this rise in blood
pressure from day 11 onward resulting in a significantly lower
MAP after 4 weeks of treatment (108 ± 7 vs. 130 ± 9 mmHg,
P < 0.001 by repeated measures ANOVA). Co-treatment with
MMF did not alter heart rate (303 ± 7 vs. 304 ± 1 beats/min,
P = 0.8).
Immunohistochemistry and Urinary
Cytokine Excretion
To confirm the anti-inflammatory effect of MMF, we analyzed
kidney T-cell infiltration and urinary cytokines (Figure 3). MMF
significantly reduced the number of CD3+ cells in cortex and
inner medulla, but not in outer medulla (Figure 3A). Urinary
IFN-γ excretion was significantly suppressed in MMF-treated
animals (Figure 3B). No statistically significant differences were
found in urinary IL-6, CCL5, and TNF-α between the two groups.
Vascular Responses
Ang II exposure led to a concentration-dependent constriction of
iliac arteries of vehicle-treated animals (pEC50 = 8.5± 0.5, n = 7).
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FIGURE 1 | Changes in intake of 0.9% NaCl (A), 24-h urine volume (B), 24-h urinary Na+ excretion (C), 24-h urinary K+ excretion (D), and the urinary Na+/K+ ratio
(E) over the total study period of 28 days of DOCA-salt-treated Sprague-Dawley rats co-treated with MMF or vehicle. Averages ± SEM are shown; n = 6–8
animals/group. Measurements were performed once a week.
FIGURE 2 | Response of the mean arterial pressure (MAP) to DOCA-salt and
co-treatment with MMF or vehicle during the 28-day study period.
Averages ± SEM are shown; n = 4 animals/group.
The Emax of Ang II in iliac arteries of MMF-treated animals was
15.3± 2.4%, compared to 47.4± 9.6% of vehicle-treated animals
(P = 0.007, Figure 4A). NO synthase (NOS) inhibition with
L-NAME greatly enhanced the Ang II response in the isolated
iliac arteries of MMF-treated animals (Emax = 73.9 ± 12.3,
P < 0.0001), but the increase was non-significant in control
animals (P = 0.16). Of note, baseline contractility following
preincubation with L-NAME was identical in both groups (data
not shown), and thus the differences in contractile response after
Ang II are not the consequence of L-NAME alone. The Ang
II type 1 (AT1) receptor antagonist irbesartan prevented the
Ang II-induced constriction in both groups. The AT2 receptor
antagonist PD123319 blocked the Ang II-induced constriction in
iliac arteries of vehicle-treated animals, but not in MMF-treated
animals (P < 0.001). ET-1 infusion caused a concentration-
dependent constriction of mesenteric arteries in vehicle-treated
animals (pEC50 = 8.3 ± 0.2, Emax = 235.2 ± 18.7%, n = 7). This
constriction was unaffected by MMF treatment (Figure 4A). ETA
receptor inhibition with BQ123 shifted the ET-1 CRC∼10-fold to
the right in mesenteric arteries of MMF-treated animals, but not
in vehicle-treated animals (P < 0.0001). ACh relaxed mesenteric
arteries after preconstriction with ET-1 in vehicle-treated
animals (pEC50 = 7.0 ± 0.2, Emax = 22.9 ± 4.4%, n = 5).
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FIGURE 3 | Immunohistochemistry data and urinary chemokines/cytokine excretion. (A) Representative images showing localization of CD3C cells (arrowheads) in a
kidney section of vehicle- and MMF-treated rats with quantification of CD3C cells in cortex, outer medulla, and inner medulla (scale bar 100 µm), and inner medulla;
(B) urine cytokine/chemokine excretion. ∗P < 0.05 vs. vehicle using Student’s t-test. IFN-γ, interferon-γ; IL-6, interleukin-6; CCL5, chemokine (C-C motif) ligand 5;
TNF-α, tumor necrosis factor-α.
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A
B
FIGURE 4 | Vascular responses to angiotensin II (Ang II), endothelin-1 (ET-1), and acetylcholine (ACh) in DOCA-salt-treated rats co-treated with MMF or vehicle.
(A) Left panel: responses of iliac arteries to Ang II in the absence (control) or presence of irbesartan, PD123319 or L-NAME. Right panel: responses of mesenteric
arteries to ET-1 in the absence or presence of BQ123 or BQ788. Contractile responses are expressed as a percentage of the response to 100 mM KCl.
(B) ACh-induced vasorelaxation. Relaxation responses are expressed as % reduction of preconstriction (with ET-1). Data are mean ± SEM of n = 4–8. ∗∗P < 0.01
and ∗∗∗P < 0.001 (pEC50 or Emax compared with control), #P < 0.001 (Emax compared with vehicle-treated rats).
This response was unaltered by MMF treatment (Figure 4B).
L-NAME completely prevented ACh-induced relaxation in ET-
1-preconstricted arteries of MMF-treated animals, but only
partially prevented this relaxation in the arteries of vehicle-
treated animals (Emax = 89.0± 2.2% vs. 62.7± 4.6%, P = 0.0009).
The latter indicates a diminished NO participation in the ACh
response, and thus, given the identical ACh response in both
groups, is suggestive for upregulation of non-NO factors to
compensate the loss of NO.
Immunoblotting of Kidney Na+
Transporters
MMF did not change the abundances of NHE3, NKCC2, NCC,
the α- and γ-subunits of ENaC (Figure 5). In addition, the
abundance of phosphorylated NCC was unchanged.
DISCUSSION
We show that MMF blunts the development of salt-sensitive
hypertension in the DOCA-salt model by reducing vascular
resistance, likely through inhibition of T cells. Results of our
Mulvany myograph studies point toward a pivotal role for the
AT2 receptor. Although DOCA-salt is a low Ang II model, a
previous study showed that mineralocorticoids regulate vascular
Ang II receptors (Schiffrin et al., 1983).
Under normal circumstances, the AT2 receptor is known to
exert either no effect or a vasodilatory effect via the production
of vascular NO (Siragy and Carey, 1997; Batenburg et al., 2004a;
Verdonk et al., 2012a). Yet, in isolated arteries of DOCA-
salt-treated rats, the AT2 receptor appears to have obtained
a constrictor function similar to that of the AT1 receptor.
In isolated arteries of rats receiving DOCA-salt and MMF
this AT2 receptor-mediated constriction was absent. Moreover,
L-NAME fully blocked the ACh-mediated vasodilation after ET-1
preconstriction in the isolated arteries of DOCA-salt + MMF-
treated rats, and displayed only a partial blocking effect in the
isolated arteries of rats exposed to DOCA-salt alone. Since the
ACh response per se was the same in both groups, these data
suggest that non-NO relaxant mechanisms (e.g., endothelium-
dependent hyperpolarizing factor(s); Batenburg et al., 2004b)
come into play after DOCA-salt, which are replaced by NO in
the presence of MMF. An MMF-induced NO upregulation is
also apparent from the huge increase in Ang II response after
L-NAME in the MMF treatment group, which did not occur
after DOCA-salt alone. Finally, the ETA receptor antagonist
BQ123 blocked ET-1-induced constriction in the isolated arteries
of MMF-treated rats, and this effect was less apparent in the
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FIGURE 5 | Immunoblots showing protein abundances in of the renal Na+ transporters sodium-hydrogen exchanger type 3 (NHE3), Na-K-Cl co-transporter
(NKCC2), Na-Cl co-transporter (NCC), NCC phosphorylated at Thr58 (pNCC), α-subunit of the epithelial sodium channel (α-ENaC), and γ-ENaC in whole kidney
homogenates of DOCA-salt-treated Sprague-Dawley rats co-treated with MMF or vehicle. No significant differences were identified. Data are mean ± SEM, n = 6–8
animals/group.
isolated arteries of rats treated with DOCA-salt only. This
is suggestive for ETA receptor upregulation after DOCA-salt.
There was no evidence for vasoconstrictor ETB receptor effects
after DOCA-salt, since BQ788 did not block ET-1-induced
vasoconstriction. Thus, our data do not support constrictor ETB
receptor upregulation, although this has been observed earlier
in Ang II-dependent hypertensive rat models (Roksnoer et al.,
2015).
When studied in young healthy animals, the AT2 receptor
stimulates vasodilation and natriuresis, thereby counteracting
the actions of the AT1 receptor, the main mediator of all
the well-known deleterious effects of Ang II (Batenburg et al.,
2004a; Padia et al., 2006; Verdonk et al., 2012a). However,
when studied in older or hypertensive animals, the AT2
receptor often loses its vasodilatory actions and instead induces
vasoconstriction, similar to the AT1 receptor (You et al., 2005;
Pinaud et al., 2007; Moltzer et al., 2010). This loss of function
might be explained by reactive oxygen species scavenging by
NO (Moltzer et al., 2010; Verdonk et al., 2012a). A further
possibility is that AT2 receptors appear on vascular smooth
muscle cells under pathophysiological conditions and act in
concert with AT1 receptors (e.g., through heterodimerization),
as opposed to their predominant, if not exclusive endothelial
presence under healthy conditions (van Esch et al., 2006;
Moltzer et al., 2010; Verdonk et al., 2012b). We now show
that the AT2 receptor also loses its vasodilatory effects during
DOCA-salt, illustrated by the fact that the Ang II-induced
constrictor responses were blocked by PD123319, an AT2
receptor antagonist (Figure 4). Furthermore, we observed that
NOS inhibition with L-NAME greatly enhanced the Ang II
contractile response in the MMF-treated animals, whereas
the increase after vehicle was non-significant, implying that
NOS is preserved in the MMF-treated animals. Indeed, in a
rat allograft model, MMF prevented endothelial dysfunction
and reduced sensitivity to vasoconstrictors by increasing NO
availability through endothelial NOS (Freguin-Bouilland et al.,
2011).
Our findings are in line with the results of Guzik et al.
(2007), who found a reduced hypertensive response and greater
vascular relaxation in Ang II-treated RAG-1−/− mice (which
lack B and T cells) than wild-type mice. Furthermore, superoxide
production is greater in wild-type than in RAG-1−/− mice after
40 days of DOCA-salt (Guzik et al., 2007). Superoxide is known to
react with NO, thereby decreasing NO availability and inducing
vasoconstriction (Gryglewski et al., 1986). Guzik et al. (2007)
investigated the abundance of the AT2 receptor in the aortic wall
by Western blot, but found no significant differences between
RAG-1−/− and wild type mice. Nevertheless, their previous
results and our data support a vasoconstrictive action of the AT2
receptor.
Compared with MMF-treated rats, the rats treated with
DOCA-salt alone had higher blood pressure, larger volumes of
fluid intake and urine output, and greater excretions of Na+
and K+ (Figures 1, 2). This suggests parallel central effects
of DOCA on salt appetite, thirst, and blood pressure, as has
been observed previously (Hamlin et al., 1988; Sapouckey et al.,
2017). Despite these differences, no changes were observed in
any of the renal tubular segments that we studied (Figure 5).
This is in contrast with recent studies analyzing the role of
inflammation on renal sodium transport in hypertensive models.
For example, IFN-γ−/− or IL-17A−/− mice had a blunted rise
in blood pressure after 2 weeks of high-dose Ang II infusion
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(Kamat et al., 2015). The IFN-γ−/− mice, but not the IL-
17A−/− mice, had a lower abundance of the phosphorylated
forms of NKCC2 and NCC than wild-type mice. Furthermore,
both IFN-γ−/− and IL-17A−/− mice had lower abundances of
NHE3 in the proximal tubules than wild-type mice (Kamat et al.,
2015). A study using cortical collecting duct cells of mice found
that treatment with IL-6 increased both the mRNA abundance
and protein expression of all ENaC subunits (Li et al., 2010).
This was accompanied by an increase in the amiloride-sensitive
Na+ current. These findings suggest that specific parts of the
immune system impair pressure natriuresis and enhance distal
tubular Na+ reabsorption, ultimately leading to hypertension.
Our findings also contrast with a recent study by Liu et al.
(2017), who found that in DOCA-salt-treated mice, CD8+ T cells
upregulated NCC expression through direct contact with distal
convoluted tubule cells. We propose the following explanations
for these differences. First, we used the DOCA-salt model which
has low levels of circulating renin and Ang II, in contrast to
the Ang II infusion model (Somers et al., 2000). Second, rats
received 0.9% NaCl as drinking water, which may have led
to a downregulation of kidney Na+ transporters. Accordingly,
higher NaCl intake in the vehicle-group (with commensurate
suppression of the renin–angiotensin system) may have blunted
possible differences between groups. Third, we cannot exclude
the possibility that changes in renal transporters were only
detectable by analyzing the phosphorylated (activated) forms of
these proteins. Finally, the duration of our experiment was twice
as long as the more commonly used DOCA-salt model, which
also includes uninephrectomy. The longer duration of our model
may have led to a new steady state with conversion from a
volume to a non-volume hypertension mechanism. Thus, in this
study, we cannot prove or reject the hypothesis that the anti-
hypertensive effect of MMF is also mediated through renal salt
handling.
A number of strengths and limitations of this study should be
mentioned. The strength of this study is that it is the first to study
both vascular resistance and kidney Na+ transporters within the
same model. A weakness is that we have not yet determined the
mechanism of the AT2 receptor-mediated constrictor response,
the identity of the non-NO component that is upregulated after
DOCA-salt, nor the expression of the ET receptors. Finally, future
studies should address whether our ex vivo observations also hold
true in vivo. For this, rats should be treated with AT2 and ETA
receptor antagonists on top of vehicle, DOCA-salt and/or MMF.
CONCLUSION
In conclusion, our findings provide additional insight into
the pathophysiologic aspects of immune involvement in the
development of hypertension. It is known that hypertensive
stimuli like old age, high salt diet and atherosclerosis cause
stress to the vascular endothelium. This stress causes “sterile
inflammation” with activation of both the innate and adaptive
immune system, mainly involving infiltration of macrophages
and T-cells in the adventitia and perivascular fat with a
subsequent production of IL-17, IFN-γ, and TNF-α, amongst
others (Epelman et al., 2015; McMaster et al., 2015; Wenzel et al.,
2016). These actions induce the production of ROS which results
in a decreased bioavailability of NO, impaired vasodilation, and
increased vascular stiffness, causing hypertension and ultimately
end-organ damage. Our results propose an important role for the
AT2 receptor, which appears to have a constrictor function under
hypertensive stimuli, which is prevented by immunosuppression
with MMF.
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